Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → L-Arginine→

L-Arginine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
74-79-3
Molecular formula
C6H14N4O2
Molecular weight
174.2 g/mol
Drug class
Proteinogenic amino acidurea-cycle intermediate and nitric-oxide precursor
Mechanism of action
Serves as a substrate for nitric oxide synthase, producing nitric oxide, and as an intermediate in the urea cycle. In urea-cycle disorders, exogenous arginine can support nitrogen disposal by promoting formation of ornithine and downstream urea-cycle intermediates, depending on the specific enzyme defect.
Indications / reported uses
  • Adjunctive management of selected urea-cycle disorders, including acute hyperammonaemia and chronic management, using formulation- and defect-specific regimens.
  • Used in selected mitochondrial disease presentations, including MELAS, under specialist clinical management.

Sources: https://www.ndf.gov.sg/about-drugs/active-ingredient/m01585/ · https://pmc.ncbi.nlm.nih.gov/articles/PMC3488504/ · https://pubmed.ncbi.nlm.nih.gov/11264451/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the L-Arginine Environmental Risk Assessment (ERA) (the L-Arginine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.